0001193125-22-141351.txt : 20220507 0001193125-22-141351.hdr.sgml : 20220507 20220505074534 ACCESSION NUMBER: 0001193125-22-141351 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220505 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39801 FILM NUMBER: 22894122 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 d349688d8k.htm 8-K 8-K
XOMA Corp DE false 0000791908 0000791908 2022-05-05 2022-05-05 0000791908 us-gaap:CommonStockMember 2022-05-05 2022-05-05 0000791908 us-gaap:SeriesAPreferredStockMember 2022-05-05 2022-05-05 0000791908 us-gaap:SeriesBPreferredStockMember 2022-05-05 2022-05-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): May 5, 2022

 

 

XOMA CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

 

 

DELAWARE   001-39801   52-2154066

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

2200 Powell Street, Suite 310, Emeryville, California 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 204-7200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

  

Trading

symbol(s):

  

Name of each exchange

on which registered:

Common Stock, $0.0075 par value   XOMA   The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share   XOMAP   The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)   XOMAO   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On May 5, 2022, XOMA Corporation issued a press release announcing its financial results for the quarter ended March 31, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Number    Description of Document
99.1    Press release entitled “XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events” dated May 5, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    XOMA CORPORATION
Date: May 5, 2022     By:  

/s/ THOMAS BURNS

      Thomas Burns
      Senior Vice President, Finance and Chief Financial Officer
 EX-99.1 2 d349688dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has announced its intention to move RZ358 into Phase 3 clinical development.

Roche’s novel bispecific antibody, in which we acquired an economic interest from Affitech SA in October 2021, received commercialization approval from the U.S. Food and Drug Administration (FDA) in January 2022 and from Japan’s Ministry of Health, Labour and Welfare (MHLW) in March 2022 for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Ended the first quarter of 2022 with cash and restricted cash of $88.6 million and no debt on XOMA’s balance sheet.

EMERYVILLE, Calif., May 5, 2022 (GLOBE NEWSWIRE) – XOMA Corporation (Nasdaq: XOMA), a biotech royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of advancing novel therapeutic candidates aimed at improving human health, reported its first quarter 2022 financial results and provided a recent operations update.

“Our team’s ability to identify and acquire the economic interests in potential therapeutic assets that have significant potential has been further validated with two events in the first months of 2022. First, since enacting of the milestone and royalty monetization strategy, an asset in our royalty portfolio became the first to achieve regulatory and commercialization approvals, leading off with the FDA in January and Japan’s MHLW at the end of the quarter. Second, we are encouraged by Regeneron’s recently announced acquisition of Checkmate and vidutolimod (CMP-001)1,” stated Jim Neal, Chairman and Chief Executive Officer of XOMA. “We congratulate our partners on their recent achievements.”

“Several other partners announced milestones in their development programs. In January 2022, Rezolute dosed the final patient with RZ358 in its Phase 2 congenital hyperinsulinism (CHI) study, which triggered a $2 million milestone payment to XOMA. We congratulate Rezolute on the RIZE Study data presented at Pediatric Endocrine Society Annual Meeting, which took place on May 12,3 and its $130 million registered direct offering and private placement4. We are pleased Rezolute and its shareholders are committed to

 

1 

https://investor.regeneron.com/news-releases/news-release-details/regeneron-acquire-checkmate-pharmaceuticals-and-its

2 

https://ir.rezolutebio.com/news-events/press-releases/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize

3 

https://ir.rezolutebio.com/news-events/ir-calendar/detail/2700/rezolute-call-to-discuss-data-presented-at-pediatric

4 

https://ir.rezolutebio.com/news-events/press-releases/detail/300/rezolute-inc-announces-aggregate-130-million-registered

moving RZ358 into Phase 3 clinical development. Additionally, Janssen expanded its cetrelimab clinical program to investigate the compound in patients with chronic hepatitis B virus. Furthermore, Palobiofarma launched a Phase 2 study with PBF-6880 in COPD patients. Each of these advancements reflect the dedication and desire of the scientists and clinicians to give patients and their families much needed hope.”

Faricimab, Affitech, and Roche Update

In October 2021, XOMA acquired an economic interest Roche’s novel bispecific antibody from Affitech SA. During the first quarter of 2022, XOMA paid $5 million in milestones to Affitech based upon the January 2022 commercialization approval from the U.S. Food and Drug Administration (FDA)5. XOMA does not owe Affitech a milestone based upon the Japan’s Ministry of Health, Labour and Welfare (MHLW) commercialization approval6, which was granted in March 2022. On April 25, 2022, Roche reported first quarter 2022 financial results, which included initial faricimab sales7.

Financial Results

XOMA recorded total revenues of $3.1 million for the first quarter of 2022, compared with $0.4 million in the first quarter of 2021. The increase for the three months ended March 31, 2022, as compared to the corresponding period of 2021, was primarily due to the $2.0 million milestone earned under the Company’s development and commercialization agreement with Rezolute and a $0.8 million milestone earned under the Takeda Collaboration Agreement.

Research and development (“R&D”) expenses were $56,000 and $61,000, respectively, for the first quarters of 2022 and 2021.

General and administrative (“G&A”) expenses were $5.1 million for the first quarter of 2022, compared to $6.7 million for the first quarter of 2021. The decrease of $1.6 million for the three months ended March 31, 2022, as compared to the corresponding period of 2021, was due primarily to a $1.9 million decrease in stock-based compensation expense for stock options and a $0.2 million decrease in consulting and deal costs, partially offset by a $0.5 million increase in personnel related expenses.

In the first quarter of 2022, G&A expenses included $1.0 million in non-cash stock-based compensation expense, compared with $2.9 million in the first quarter of 2021. XOMA’s net cash used in operations in the first quarter of 2022 was $1.0 million, as compared with $0.9 million during the first quarter of 2021.

Other expense, net was $0.2 million for the first quarter of 2022, compared to other expense, net of $0.7 million in the corresponding quarter of 2021. The fluctuation in other (expense) income, net between the quarters ended March 31, 2022 and 2021, is primarily due to the change in the fair value of equity securities XOMA holds in Rezolute, Inc.

 

5 

https://www.roche.com/media/releases/med-cor-2022-01-31

6 

https://www.roche.com/investors/updates/inv-update-2022-03-28

7 

https://www.roche.com/media/releases/med-cor-2022-04-25

Net loss for the first quarter of 2022 was $2.3 million, compared to net loss of $7.4 million for the first quarter of 2021.

On March 31, 2022, XOMA had cash, cash equivalents and restricted cash of $88.6 million. On January 18, 2022, the Company paid cash dividends on the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) equal to $0.53906 per share and cash dividends on the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) equal to $0.52344 per depositary share. The Company ended December 31, 2021, with cash and restricted cash of $95.4 million. After paying its remaining debt obligations in the second quarter of 2021, XOMA has no debt on its balance sheet. The Company continues to believe its current cash position will be sufficient to fund XOMA’s operations for multiple years.

About XOMA Corporation

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

Forward-Looking Statements/Explanatory Notes

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to faricimab, the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, and XOMA’s cash sufficiency forecast. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except faricimab, are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except per share amounts)

 

     Three Months Ended
March 31,		  
     2022      2021  

Revenues:

      

Revenue from contracts with customers

    $ 2,750      $ 19  

Revenue recognized under units-of-revenue method

      357        356  
  

 

 

     

 

 

  

Total revenues

      3,107        375  
  

 

 

     

 

 

  

Operating expenses:

      

Research and development

      56        61  

General and administrative

      5,116        6,741  
  

 

 

     

 

 

  

Total operating expenses

      5,172        6,802  
  

 

 

     

 

 

  

Loss from operations

      (2,065 )       (6,427 ) 

Other (expense) income, net:

      

Interest expense

      —          (289 ) 

Other (expense) income, net

      (215 )       (657 ) 
  

 

 

     

 

 

  

Net loss and comprehensive loss

    $ (2,280 )     $ (7,373 ) 

Less: accumulated dividends on Series A and Series B preferred stock

    $ (1,368 )     $ (530 ) 
  

 

 

     

 

 

  

Net loss available to common stockholders, basic and diluted

    $ (3,648 )     $ (7,903 ) 
  

 

 

     

 

 

  

Basic and diluted net loss per share available to common stockholders

    $ (0.32 )     $ (0.70 ) 
  

 

 

     

 

 

  

Weighted average shares used in computing basic and diluted net loss per share available to common stockholders

      11,330        11,240  
  

 

 

     

 

 

  

XOMA CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except share and per share amounts)

 

     March 31,
2022		      December 31,
2021		  
ASSETS              

Current assets:

      

Cash and cash equivalents

    $ 87,796      $ 93,328  

Restricted cash

      837        2,049  

Short-term equity securities

      547        774  

Trade and other receivables, net

      25        209  

Prepaid expenses and other current assets

      409        613  
  

 

 

     

 

 

  

Total current assets

      89,614        96,973  

Property and equipment, net

      12        13  

Operating lease right-of-use assets

      158        200  

Long-term royalty and commercial payment receivables

      69,075        69,075  

Other assets - long term

      301        301  
  

 

 

     

 

 

  

Total assets

    $ 159,160      $ 166,562  
  

 

 

     

 

 

  
LIABILITIES AND STOCKHOLDERS’ EQUITY              

Current liabilities:

      

Accounts payable

    $ 787      $ 1,072  

Accrued and other liabilities

      855        525  

Income taxes payable

      —          91  

Contingent consideration under royalty purchase agreements and commercial purchase payment agreements

      3,075        8,075  

Operating lease liabilities

      182        195  

Unearned revenue recognized under units-of-revenue method

      1,623        1,641  

Preferred stock dividend accrual

      1,368        1,368  
  

 

 

     

 

 

  

Total current liabilities

      7,890        12,967  

Unearned revenue recognized under units-of-revenue method – long-term

      11,346        11,685  

Long-term operating lease liabilities

      —          34  
  

 

 

     

 

 

  

Total liabilities

      19,236        24,686  
  

 

 

     

 

 

  

Stockholders’ equity:

      

Preferred Stock, $0.05 par value, 1,000,000 shares authorized:

 

8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at March 31, 2022 and December 31, 2021

      49        49  

8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at March 31, 2022 and December 31, 2021

      —          —    

Convertible preferred stock, 5,003 issued and outstanding at March 31, 2022 and December 31, 2021

      —          —    

Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,409,935 and 11,315,263 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

      86        85  

Additional paid-in capital

      1,307,357        1,307,030  

Accumulated deficit

      (1,167,568 )       (1,165,288 ) 
  

 

 

     

 

 

  

Total stockholders’ equity

      139,924        141,876  
  

 

 

     

 

 

  

Total liabilities and stockholders’ equity

    $ 159,160      $ 166,562  
  

 

 

     

 

 

  

# # #

 

Investor contacts:   
Juliane Snowden    Justin Frantz
XOMA    Solebury Trout
+1-646-438-9754    +1-937-441-9731
juliane.snowden@xoma.com    jfrantz@soleburytrout.com

Media contact:

Kathy Vincent

KV Consulting & Management

+1-310-403-8951

kathy@kathyvincent.com

EX-101.SCH 3 tmb-20220505.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 tmb-20220505_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 tmb-20220505_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series B Preferred Stock [Member] EX-101.PRE 6 tmb-20220505_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g349688g0505030851372.jpg GRAPHIC begin 644 g349688g0505030851372.jpg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htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 05, 2022
Document And Entity Information [Line Items]  
Entity Registrant Name XOMA Corp
Entity Incorporation State Country Code DE
Amendment Flag false
Entity Central Index Key 0000791908
Document Type 8-K
Document Period End Date May 05, 2022
Entity File Number 001-39801
Entity Tax Identification Number 52-2154066
Entity Address, Address Line One 2200 Powell Street
Entity Address, Address Line Two Suite 310
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code (510)
Local Phone Number 204-7200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, $0.0075 par value
Trading Symbol XOMA
Security Exchange Name NASDAQ
Series A Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share
Trading Symbol XOMAP
Security Exchange Name NASDAQ
Series B Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)
Trading Symbol XOMAO
Security Exchange Name NASDAQ
XML 9 d349688d8k_htm.xml IDEA: XBRL DOCUMENT 0000791908 2022-05-05 2022-05-05 0000791908 us-gaap:CommonStockMember 2022-05-05 2022-05-05 0000791908 us-gaap:SeriesAPreferredStockMember 2022-05-05 2022-05-05 0000791908 us-gaap:SeriesBPreferredStockMember 2022-05-05 2022-05-05 XOMA Corp DE false 0000791908 8-K 2022-05-05 001-39801 52-2154066 2200 Powell Street Suite 310 Emeryville CA 94608 (510) 204-7200 false false false false Common Stock, $0.0075 par value XOMA NASDAQ 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share XOMAP NASDAQ Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) XOMAO NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 4 23 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d349688d8k.htm d349688dex991.htm tmb-20220505.xsd tmb-20220505_def.xml tmb-20220505_lab.xml tmb-20220505_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d349688d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "tmb-20220505_def.xml" ] }, "inline": { "local": [ "d349688d8k.htm" ] }, "labelLink": { "local": [ "tmb-20220505_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20220505_pre.xml" ] }, "schema": { "local": [ "tmb-20220505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 3, "nsprefix": "tmb", "nsuri": "http://imetrix.edgar-online.com/20220505", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d349688d8k.htm", "contextRef": "duration_2022-05-05_to_2022-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d349688d8k.htm", "contextRef": "duration_2022-05-05_to_2022-05-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "tmb_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://imetrix.edgar-online.com/20220505", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "tmb_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://imetrix.edgar-online.com/20220505", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://imetrix.edgar-online.com//20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001193125-22-141351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-141351-xbrl.zip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end